Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

Study Z-033

The first multi-center efficacy trial Z-033 was conducted in 53 sites in the United States and Canada, with 8 additional sites in Europe. The study involved 667 patients under the supervision of lead investigator, Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York. Patients entered a 1- to 4-week screening period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients were then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and 26 followed by placebo at Week 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52.

The study Z-033 demonstrated no clear differences in overall efficacy with all 3 groups showing an improvement in IPSS of approximately 4 points that was maintained throughout the 52 weeks. There was a slight advantage in favor of the main active treatment arm (Arm A) up to Week 46 of the follow-up, which was no longer de
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... June 29 Sirnaomics, Inc. ( www.sirnaomics.com ) ... (Small Business Innovation Research) grants from National Cancer Institute ... Diseases  (NIAID), of National Institute of Health ... 2007, is dedicated to developing RNA interference (RNAi) therapeutics ...
... June 29, 2010 Cardio3,BioSciences, a leading Belgian biotechnology ... positive safety data and preliminary efficacy results from its,clinical trial of ... , , ... showed C-Cure to have a very good safety profile with no ...
... DALLAS, Texas , June 29, 2010 , ... - ReportsandReports Announces it Will Carry the Disease and Therapy,Review: Impetigo Market ... Browse the complete ... The Impetigo Disease and ...
Cached Biology Technology:Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 2Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 3Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 3Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 5Disease and Therapy Review: Impetigo Now Available at ReportsandReports 2Disease and Therapy Review: Impetigo Now Available at ReportsandReports 3Disease and Therapy Review: Impetigo Now Available at ReportsandReports 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 5
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):The cultural side of science communication 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: